BioRestorative TherapiesBRTX
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
15% more funds holding
Funds holding: 13 [Q2] → 15 (+2) [Q3]
0.01% less ownership
Funds ownership: 3.9% [Q2] → 3.9% (-0.01%) [Q3]
13% less capital invested
Capital invested by funds: $537K [Q2] → $468K (-$69.4K) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for BRTX.
